Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.
Posted 05 March 2012 | By Alexander Gaffney, RAC
Australia's Therapeutic Goods Administration (TGA) said 2 March that it is working to establish "an ongoing collaboration in international inspection of [Active Pharmaceutical Ingredient (API)] manufacturers and [an] increase in the number of regulators participating" in their good manufacturing practice (GMP) pilot program.
TGA noted that this collaboration has resulted in a governing document for the program, which will allow the World Health Organization to become a new partner.
The document is "the first step the expansion of the international program which fosters cooperation and sharing of resources between regulators for a better inspectional coverage of API manufacturers worldwide and contributes to the realization of the WHO objective of safe and effective medicines for all," said TGA.
Read more:
TGA - Update: Improving international cooperation between regulators
Tags: Latest News, Inspection, australia, API, program, GMP